Pharmaceuticals & Therapeutics

A blockbuster drug for chronic illness gets a generic rival, promising huge savings. But is it just about price? A deep dive into the strategy behind the new pill.

Australian biotech Gelteq is opening a China R&D hub to chase explosive growth, but its bold move into a $60B market comes with significant geopolitical risks.

Scilex sets a date to pay out Semnur stock to its shareholders. We dig into whether this is a true value unlock or a move born from financial pressure.

Spectrum Health's new Lowell facility isn't just another clinic; it's a strategic play to rewire recovery by integrating care in a state on high alert.

As the deadly Bundibugyo Ebola strain spreads with no approved vaccine, a small pharma company is positioning its cancer drug as a potential broad-spectrum shield.

By expanding its circular carbon black production to China, Orion S.A. is not just opening a new facility; it's executing a global strategy to dominate the next era of tire manufacturing.

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

A first-in-class drug aims to calm overactive immune cells, offering a new blueprint for treating diseases like rheumatoid arthritis. But can it deliver?

Fresh Del Monte's new partnership with the Pirates isn't just advertising. It's a strategic move solidifying its deep economic and community roots in Pittsburgh.

With its first product launch, Daré Bioscience enters a new commercial era. But can a single probiotic launch secure the future of its ambitious pipeline?

SciSparc's subsidiary just spent nearly C$10M on a quantum computing firm. This is the operational innovation designed to fix billion-dollar clinical trial failures.

With a 'best-in-class' obesity drug and a novel MASH therapy, clinical-stage MetaVia is set to woo investors. Can its science stand out against the giants?

A crucial CAP accreditation for its advanced CNS cancer test positions Plus Therapeutics to unlock new markets and redefine patient care with precision diagnostics.

A Florida biotech is using a novel gene therapy to correct aging-related errors. But the real story is its funding: a decentralized, crypto-style model.

With an FDA decision just weeks away, Ionis's olezarsen could redefine care for a debilitating condition, marking a pivotal moment for RNA-targeted medicine.

A new collaborative funding model is accelerating a revolutionary approach to ALS treatment, targeting the disease's core mechanism. Here's the why behind the buy.

A strategic shift in research funding is backing novel science that targets glial cells, not just neurons. This could be a critical turning point in the fight against ALS.

Barcelona's Ona Therapeutics secures $86.6M to advance its novel antibody-drug conjugates, moving beyond existing treatments to tackle resistant cancers.

Clariant's successful €500M Eurobond return signals massive investor trust. This move isn't just about debt; it's a strategic play to fund growth.

Jade Biosciences secures a massive $150M offering to fuel its promising drug pipeline, but the deal's pricing reveals the intense pressures of the biotech market.